High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized,placebo-controlled,phase 2 trial

Abstract

Background:

Erythropoietin (EPO) is a part of an endogenous neuroprotective system in the brain and may address pathophysiological mechanisms in progressive multiple sclerosis (MS).

Objective:

To evaluate a treatment effect of EPO on progressive MS.

Methods:

This was a single-center, randomized, double-blind, placebo-controlled phase 2 trial, in which 52 patients with secondary or primary progressive MS were allocated to treatment with recombinant EPO (48,000 IU) or placebo, administered intravenously 17 times during 24 weeks. Patients had an Expanded Disability Status Score (EDSS) from 4 to 6.5 and clinical progression without relapses in the 2 preceding years. The primary outcome was the change in a composite measure of maximum gait distance, hand dexterity, and cognition from baseline to 24 weeks.

Results:

A total of 50 patients completed the study. Venesection was performed often but no thromboembolic events occurred. We found no difference in the primary outcome between the EPO and the placebo group using the intention-to-treat principle (p = 0.22). None of the secondary outcomes, neither clinical nor magnetic resonance imaging (MRI) measures showed any significant differences.

Conclusion:

This study provides class II evidence that treatment with high-dose EPO is not an effective treatment in patients with moderately advanced progressive MS.

Keywords

Erythropoietin progressive multiple sclerosis

Get full access to this article

View all access options for this article.

References

Lublin

Reingold

Cohen

. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 2014; 83: 278–286.

Mahad

Trapp

Lassmann

. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol 2015; 14: 183–193.

Confavreux

Vukusic

Moreau

. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430–1438.

Ontaneda

Fox

Chataway

. Clinical trials in progressive multiple sclerosis: Lessons learned and future perspectives. Lancet Neurol 2015; 14: 208–223.

Brines

Cerami

. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005; 6: 484–494.

Cervellini

Ghezzi

Mengozzi

. Therapeutic efficacy of erythropoietin in experimental autoimmune encephalomyelitis in mice, a model of multiple sclerosis. Methods Mol Biol 2013; 982: 163–173.

Ehrenreich

Fischer

Norra

. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 2007; 130: 2577–2588.

Polman

Reingold

Edan

. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.” Ann Neurol 2005; 58: 840–846.

Kurtzke

. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1452.

10.

Barkhof

Rocca

Francis

. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol 2003; 53: 718–724.

11.

Kharagjitsingh

Korevaar

Vandenbroucke

. Incidence of recombinant erythropoietin (EPO) hyporesponse, EPO-associated antibodies, and pure red cell aplasia in dialysis patients. Kidney Int 2005; 68: 1215–1222.

12.

Polman

Rudick

. The multiple sclerosis functional composite: A clinically meaningful measure of disability. Neurology 2010; 74 (Suppl. 3): S8–S15.

13.

Reitan

. The relation of the trail making test to organic brain damage. J Consult Psychol 1955; 19: 393–394.

14.

Langdon

Amato

Boringa

. Recommendations for a brief international cognitive assessment for multiple sclerosis (BICAMS). Mult Scler 2012; 18: 891–898.

15.

Ware

Jr Sherbourne

. The MOS 36-item short-form health survey (SF-36). I: Conceptual framework and item selection. Med Care 1992; 30: 473–483.

16.

Juul

Anderson

. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 1998; 43: 40–49.

17.

Agnello

Bigini

Villa

. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 2002; 952: 128–134.

18.

Chong

Shang

. Targeting erythropoietin for chronic neurodegenerative diseases. Expert Opin Ther Targets 2013; 17: 707–720.

19.

Maeda

Yuan

. Beneficial effect of erythropoietin on experimental allergic encephalomyelitis. Ann Neurol 2004; 56: 767–777.

20.

Diem

Sattler

Merkler

. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain 2005; 128: 375–385.

21.

Sattler

Merkler

Maier

. Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. Cell Death Differ 2004; 11(Suppl. 2): S181–S192.

22.

Zhang

Cui

. Erythropoietin treatment improves neurological functional recovery in EAE mice. Brain Res 2005; 1034: 34–39.

23.

Hagemeyer

Boretius

Ott

. Erythropoietin attenuates neurological and histological consequences of toxic demyelination in mice. Mol Med 2012; 18: 628–635.

24.

Gold

Linington

Lassmann

. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006; 129: 1953–1971.

25.

Leist

Ghezzi

Grasso

. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004; 305: 239–242.

26.

Erbayraktar

Grasso

Sfacteria

. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA 2003; 100: 6741–6746.

27.

Savino

Pedotti

Baggi

. Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. J Neuroimmunol 2006; 172: 27–37.

28.

Thorne

Moore

Robertson

. Lack of TIMP-1 increases severity of experimental autoimmune encephalomyelitis: Effects of darbepoetin alfa on TIMP-1 null and wild-type mice. J Neuroimmunol 2009; 211: 92–100.

29.

Creange

Lefaucheur

Balleyguier

. Iron depletion induced by bloodletting and followed by rhEPO administration as a therapeutic strategy in progressive multiple sclerosis: A pilot, open-label study with neurophysiological measurements. Neurophysiol Clin 2013; 43: 303–312.

30.

Najmi

Azimi

. Efficacy of combination therapy with erythropoietin and methylprednisolone in clinical recovery of severe relapse in multiple sclerosis. Acta Neurol Belg 2014; 114: 273–278.

31.

Wustenberg

Begemann

Bartels

. Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia. Mol Psychiatry 2011; 16: 26–36.

32.

Miskowiak

Vinberg

Christensen

. Recombinant human erythropoietin for treating treatment-resistant depression: A double-blind, randomized, placebo-controlled phase 2 trial. Neuropsychopharmacology 2014; 39: 1399–1408.

33.

Miskowiak

Vinberg

Macoveanu

. Effects of erythropoietin on hippocampal volume and memory in mood disorders. Biol Psychiatry 2014; 78(4): 270–247.

34.

Ehrenreich

Weissenborn

Prange

. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009; 40: e647–e656.

35.

Singh

. Is there a deleterious effect of erythropoietin in end-stage renal disease? Kidney Int 2011; 80: 569–571.

36.

Weiner

Miskulin

Seefeld

. Reducing versus discontinuing erythropoietin at high hemoglobin levels. J Am Soc Nephrol 2007; 18: 3184–3191.

37.

Pfeffer

Burdmann

Chen

. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019–2032.

38.

Ogunshola

Bogdanova

. Epo and non-hematopoietic cells: What do we know? Methods Mol Biol 2013; 982: 13–41.

39.

Tourbah

Frenay

Edan

. Effect of MD1003 (high doses of biotin) in progressive multiple sclerosis: Results of a pivotal phase III randomised double blind placebo controlled study. In: The 67th annual meeting of the American academy of neurology, Washington, DC, 18–25 April 2015.

40.

Montalban

Hemmer

Rammohan

. Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis—Results of the placebo-controlled, double-blind, Phase III ORATORIO study. Mult Scler 2015; 86: 708–808.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.46 MB

0.10 MB